Here’s whether Roivant Sciences Ltd. Common Shares (ROIV) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+1.03% over 10 days); RSI 47 — healthy momentum range; strong 1-year return of +155.2%. Concerns: below the 50-day MA (medium-term momentum negative). Currently 12.8% off its 52-week high. Score: +4/7.
ROIV is holding above its long-term 200-day MA ($22.75) but has slipped below the 50-day MA ($28.71), pointing to short-term weakness in an otherwise intact trend. An RSI of 47.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +155.2% compares to +24.4% for SPY (beat the market by 130.8%).
$10,000 invested 1 year ago→ $25,518 today
vs. S&P 500 (SPY) — same period beat market by 130.8%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($22.75)
✗Above 50-day MA ($28.71)
✓RSI(14) neutral zone (30–70) — currently 47.2
✓Positive return (+155.2%)
!Within 10% of period high (−12.8%)
Period Range $28.58
$10.71$32.79
RSI (14) 47.2
0 · OversoldOverbought · 100
Key Metrics
Price$28.58
Period Return+155.2%
Period High$32.79
Period Low$10.71
Drawdown−12.8%
MA-50$28.71
MA-200$22.75
RSI (14)47.2
Avg Volume (30d)6.1M
vs. SPYbeat by 130.8%
Return Rank#138 of 1245
Trend Signals
Price is above the 200-day moving average ($22.75)